Rubric Capital Management (New York)’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Rubric Capital Management (New York)’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-7,000,000	Closed	-$3.04M	–	107
2022 Q4	$3.04M	Hold	7,000,000	–	–	0.13%	82
2022 Q3	$1.96M	Buy	7,000,000 +988,995	+16%	+$339K	0.1%	78
2022 Q2	$2.17M	Buy	6,011,005 +3,011,005	+100%	+$1.25M	0.11%	78
2022 Q1	$2.01M	Hold	3,000,000	–	–	0.07%	71
2021 Q4	$3.87M	Hold	3,000,000	–	–	0.18%	57
2021 Q3	$6.51M	Hold	3,000,000	–	–	0.18%	47
2021 Q2	$8.19M	Buy	3,000,000 +499,582	+20%	+$1.24M	0.52%	42
2021 Q1	$6.53M	Buy	2,500,418 +165,218	+7%	+$467K	0.38%	51
2020 Q4	$6.49M	Buy	2,335,200 +1,875,000	+407%	+$5.46M	0.48%	49
2020 Q3	$2.13M	Hold	460,200	–	–	0.2%	59
2020 Q2	$1.3M	Hold	460,200	–	–	0.15%	50
2020 Q1	$1.12M	Buy	+460,200	New	+$1.66M	0.18%	50

Other funds holding SIOX

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Rubric Capital Management (New York)'s SIOX Position: Q1 2023 in Review

Rubric Capital Management (New York) sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2023, closing a stake of 7,000,000 shares — an estimated $3.04M sold.

Rubric Capital Management (New York) first reported a position in SIOX in Q1 2020 and held it in 12 quarters. The position peaked at $8.19M in Q2 2021. 4 funds tracked by Wall St. Rank hold SIOX as of Q1 2023.

Rubric Capital Management (New York) reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Rubric Capital Management (New York) sold 7,000,000 Sio Gene Therapies Inc. Common Stock shares in Q1 2023, an estimated $3.04M.
Rubric Capital Management (New York) first reported a position in Sio Gene Therapies Inc. Common Stock in Q1 2020 and held it in 12 quarters.
Rubric Capital Management (New York)'s Sio Gene Therapies Inc. Common Stock position peaked at $8.19M in Q2 2021.
4 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2023.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2023, filed 12 May 2023.